Tysabri and PML: Differentiating Symptoms from Diagnosis

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

Legacy of General Health Information and the Emergence of Tysabri Risks

If you or a loved one is taking Tysabri and experiencing new neurological symptoms, it's natural to worry about PML. Yet not every symptom means active infection—distinguishing early signs from other conditions is critical. Decades of pharmacovigilance and clinical research have established a framework for monitoring and diagnosis, which this page explains in clear terms.

Understanding Tysabri and Its Link to Progressive Multifocal Leukoencephalopathy

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can vary, but common features include progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. Diagnosis relies on a combination of clinical assessment, brain imaging (typically MRI showing demyelinating lesions), and laboratory detection of JCV DNA in cerebrospinal fluid. In a large retrospective cohort study of 456 PML patients observed between 1987 and 2024, the disease was characterized as a severe demyelinating condition with variable survival depending on underlying disease and time of diagnosis (https://pubmed.ncbi.nlm.nih.gov/40922664/). The pharmacological mechanism of Tysabri involves binding to alpha-4 integrins on the surface of immune cells, thereby preventing their migration across the blood-brain barrier into the central nervous system. While this action reduces inflammatory activity in multiple sclerosis, it also impairs immune surveillance in the brain, creating an environment permissive for JCV reactivation and PML development.

Risk Factors and FDA Warnings for Tysabri-Associated PML

The FDA-approved labeling for Tysabri includes a boxed warning stating that the drug increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML compared to those who are negative (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In clinical trials, PML occurred in three patients: two among 1869 multiple sclerosis patients treated for a median of 120 weeks (both had also received interferon beta-1a), and one among 1043 Crohn's disease patients after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The mechanistic pathway linking Tysabri to PML is rooted in its immunomodulatory effects. By blocking lymphocyte trafficking into the brain, Tysabri reduces the normal immune surveillance that controls JCV replication. This allows the virus to proliferate in oligodendrocytes, leading to demyelination and the characteristic brain lesions of PML. The risk is highest in patients with detectable anti-JCV antibodies, as these antibodies indicate prior exposure to the virus and potential for reactivation. The duration of therapy is also critical, with risk increasing significantly after two years of continuous treatment. Prior immunosuppressant use compounds this risk by further compromising the immune system's ability to control JCV.

Legal Considerations for Tysabri PML Patients

Regarding the adequacy of warnings, the Tysabri label contains a boxed warning that clearly states the increased risk of PML and identifies the three major risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label also instructs healthcare professionals to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first such sign (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which aims to ensure that patients are informed of the risks and that monitoring is conducted (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, some patients and their families may question whether the risks were adequately communicated, particularly in cases where PML developed despite adherence to monitoring protocols. For affected patients, attorney-related considerations often involve evaluating whether the treating physician or the manufacturer provided sufficient information about PML risk and whether the patient's individual risk factors were properly assessed. The timeline between exposure and documented harm is variable; PML can develop after months to years of Tysabri treatment, with the risk increasing with longer duration. In clinical trials, cases were observed after 8 doses (approximately 2 months) and after a median of 120 weeks (approximately 2.3 years) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This variability underscores the importance of ongoing monitoring and early intervention. Patients who develop PML may face severe disability or death, and legal action may be pursued to seek compensation for medical expenses, lost income, and pain and suffering. Attorneys specializing in Tysabri-related PML cases typically review medical records to determine if risk factors were identified and if appropriate monitoring occurred.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how is it linked to PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus, due to its immunosuppressive effects that reduce immune surveillance in the brain (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the main risk factors for developing PML while on Tysabri?

The three major risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What legal options are available for patients who developed PML after Tysabri use?

Patients may pursue legal action against the manufacturer or healthcare providers for inadequate warnings or failure to monitor risk factors. An attorney can review medical records to assess if proper protocols were followed and seek compensation for damages.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.